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Background: Further study is needed to determine which patient characteristics and lesion criteria derive the greatest benefit from carotid 
artery stenting (CAS). SAPPHIRE Worldwide is a large scale multicenter post-approval study to evaluate CAS with distal embolic protection using the 
Cordis PRECISE® Nitinol Stent and ANGIOGUARD™ XP/RX Emboli Capture Guidewire. This is the largest study to date to enroll over 10,000 patients 
undergoing CAS with distal protection.
Methods: Patients were enrolled with either symptomatic stenosis ≥50% or asymptomatic stenosis ≥80% and considered at high risk for surgery. 
Inclusion criteria included adherence to current FDA-approved labeling with these devices. The primary endpoint of major adverse events (MAE) at 
30 days included any death, myocardial infarction or stroke.
Results: Enrollment began October, 2006 and is ongoing. Data were previously reported on 7,509 patients, of whom 2,159 (29%) were 
symptomatic and 5,350 (71%) were asymptomatic. Overall, the MAE rate at 30 days was 4.5% (death1.3%, MI 0.7%, stroke 3.3%). There was 
a significant increase in the combined rate of stroke or death at 30 days between symptomatic and asymptomatic patients (6.3% vs. 3.2%, 
p<0.0001), and patients 75 years of age and older compared to younger patients (5.6% vs. 2.8%, p<0.0001). The 30-day stroke or death rate did 
not differ significantly among operator experience or volume of centers. To date, 10,000 patients have been enrolled and completed 30-day follow-
up. Final data will be available and presented on the 10,000 patients at time of presentation.
Conclusion: These data compare favorably to other reports of CAS in a high-surgical risk population and are similar to results recently reported in 
the CREST trial comparing CAS to surgery in a non-high surgical risk population.
